Literature DB >> 19808564

Rapid initial reduction of hyperenhanced myocardium after reperfused first myocardial infarction suggests recovery of the peri-infarction zone: one-year follow-up by MRI.

Henrik Engblom1, Erik Hedström, Einar Heiberg, Galen S Wagner, Olle Pahlm, Håkan Arheden.   

Abstract

BACKGROUND: The time course and magnitude of infarct involution, functional recovery, and normalization of infarct-related electrocardiographic (ECG) changes after acute myocardial infarction (MI) are not completely known in humans. We sought to explore these processes early after MI and during infarct-healing using cardiac MRI. METHODS AND
RESULTS: Twenty-two patients with reperfused first-time MI were examined by MRI and ECG at 1, 7, 42, 182, and 365 days after infarction. Global left ventricular function and regional wall thickening were assessed by cine MRI, and injured myocardium was depicted by delayed contrast-enhanced MRI. Infarct size by ECG was estimated by QRS scoring. The reduction of hyperenhanced myocardium occurred predominantly during the first week after infarction (64% of the 1-year reduction). Furthermore, during the first week the amount of nonhyperenhanced myocardium increased significantly (P<0.001), although the left ventricular mass remained unchanged. Left ventricular ejection fraction increased gradually, whereas the greater the regional transmural extent of hyperenhancement at day 1, the later the recovery of regional wall thickening. Regional wall thickening decreased progressively with increasing initial transmural extent of hyperenhancement (P(trend)<0.0001). The time course and magnitude of decrease in QRS score corresponded with the reduction of hyperenhanced myocardium.
CONCLUSIONS: The early reduction of hyperenhanced myocardium may reflect recovery of hyperenhanced, reversibly injured myocardium, which must be considered when predicting functional recovery from delayed contrast-enhanced MRI findings early after infarction. Also, the time course and magnitude for reduction of hyperenhanced myocardium were associated with normalization of infarct-related ECG changes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808564     DOI: 10.1161/CIRCIMAGING.108.802199

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  43 in total

1.  Time-dependency, predictors and clinical impact of infarct transmurality assessed by magnetic resonance imaging in patients with ST-elevation myocardial infarction reperfused by primary coronary percutaneous intervention.

Authors:  Suzanne de Waha; Ingo Eitel; Steffen Desch; Georg Fuernau; Philipp Lurz; Deniz Haznedar; Matthias Grothoff; Matthias Gutberlet; Gerhard Schuler; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2011-11-10       Impact factor: 5.460

2.  Relationship and prognostic value of microvascular obstruction and infarct size in ST-elevation myocardial infarction as visualized by magnetic resonance imaging.

Authors:  Suzanne de Waha; Steffen Desch; Ingo Eitel; Georg Fuernau; Philipp Lurz; Anja Leuschner; Matthias Grothoff; Matthias Gutberlet; Gerhard Schuler; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2012-06       Impact factor: 5.460

3.  Myocardial area at risk after ST-elevation myocardial infarction measured with the late gadolinium enhancement after scar remodeling and T2-weighted cardiac magnetic resonance imaging.

Authors:  Jacob Lønborg; Thomas Engstrøm; Anders B Mathiasen; Niels Vejlstrup
Journal:  Int J Cardiovasc Imaging       Date:  2011-10-05       Impact factor: 2.357

4.  Consideration of the impact of reperfusion therapy on the quantitative relationship between the Selvester QRS score and infarct size by cardiac MRI.

Authors:  Stephanie A M Knippenberg; Galen S Wagner; Joey F A Ubachs; Anton Gorgels; Erik Hedström; Håkan Arheden; Henrik Engblom
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-07       Impact factor: 1.468

5.  Suboptimal performance of cardiovascular magnetic resonance imaging for the assessment of myocardial viability at the early phase of an acute coronary syndrome: Usefulness of SPECT myocardial perfusion imaging.

Authors:  Loïc Djaileb; Adrien Jankowski; Marjorie Canu; Alex Calizzano; Laurent Riou; Alexis Broisat; Daniel Fagret; Catherine Ghezzi; Gerald Vanzetto; Gilles Barone-Rochette
Journal:  J Nucl Cardiol       Date:  2018-06-26       Impact factor: 5.952

Review 6.  Post myocardial infarction of the left ventricle: the course ahead seen by cardiac MRI.

Authors:  Pier Giorgio Masci; Jan Bogaert
Journal:  Cardiovasc Diagn Ther       Date:  2012-06

7.  Early Gadolinium Enhancement for Determination of Area at Risk: A Preclinical Validation Study.

Authors:  Sophia Hammer-Hansen; Steve W Leung; Li-Yueh Hsu; Joel R Wilson; Joni Taylor; Anders M Greve; Jens Jakob Thune; Lars Køber; Peter Kellman; Andrew E Arai
Journal:  JACC Cardiovasc Imaging       Date:  2016-09-21

8.  Cardiovascular magnetic resonance of the myocardium at risk in acute reperfused myocardial infarction: comparison of T2-weighted imaging versus the circumferential endocardial extent of late gadolinium enhancement with transmural projection.

Authors:  Joey F A Ubachs; Henrik Engblom; David Erlinge; Stefan Jovinge; Erik Hedström; Marcus Carlsson; Håkan Arheden
Journal:  J Cardiovasc Magn Reson       Date:  2010-03-29       Impact factor: 5.364

9.  Assessment of myocardium at risk with contrast enhanced steady-state free precession cine cardiovascular magnetic resonance compared to single-photon emission computed tomography.

Authors:  Peder Sörensson; Einar Heiberg; Nawsad Saleh; Frederic Bouvier; Kenneth Caidahl; Per Tornvall; Lars Rydén; John Pernow; Håkan Arheden
Journal:  J Cardiovasc Magn Reson       Date:  2010-04-30       Impact factor: 5.364

10.  Design and validation of Segment--freely available software for cardiovascular image analysis.

Authors:  Einar Heiberg; Jane Sjögren; Martin Ugander; Marcus Carlsson; Henrik Engblom; Håkan Arheden
Journal:  BMC Med Imaging       Date:  2010-01-11       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.